Pricing Log in Create free account

Polaryx Therapeutics, Inc. (PLYX) vs Retension Pharmaceuticals, Inc. (RTSN)

Polaryx Therapeutics, Inc. and Retension Pharmaceuticals, Inc. are both Biotechnology companies. Polaryx Therapeutics, Inc. and Retension Pharmaceuticals, Inc. are of similar size ($89.3M and $86.7M).

Valuation

Metric PLYX RTSN Biotechnology median
P/E n/m — 10.60
P/S n/m — 9.40
P/B 8.12 — 2.13
Price to free cash flow n/m — 25.18
EV/EBITDA n/m — 0.66
EV/Sales n/m — 9.02
Earnings yield (11.77%) — (32.88%)
Free cash flow yield (9.27%) — (23.13%)

Profitability

Metric PLYX RTSN Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% — 0.00%
Return on equity 0.00% — (51.96%)
Return on assets (169.05%) — (46.06%)
Return on invested capital 0.00% — 0.00%

Growth

Metric PLYX RTSN Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 77.72% — 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric PLYX RTSN Biotechnology median
Debt to equity 0.00 — 0.00
Current ratio 13.53 — 4.97
Net debt to EBITDA 0.66 — 1.01

Dividend

Metric PLYX RTSN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PLYX RTSN Biotechnology median
Market cap 86.73m 89.31m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack